PRE-IND STUDIES OF FIRST-GENERATION DUAL-TARGETED, FINE-TUNED, IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC)

$4,650,116FY2021Defense Health AgencyDOD

Dana-Farber Cancer Institute, Inc.

Investigators

PRE-IND STUDIES OF FIRST-GENERATION DUAL-TARGETED, FINE-TUNED, IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC) · GrantIndex